ASTX660/Tolinapant is a dual antagonist of XIAP and cIAP is currently under investigation in phase 1/2 studies in solid tumors and in combination with hypomethylating agents in AML[105,106]. The gene discussed is XIAP; the disease is acute myeloid leukemia.